- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01449370
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
January 13, 2017 updated by: Millennium Pharmaceuticals, Inc.
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
Study Overview
Study Type
Interventional
Enrollment (Actual)
125
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain
-
-
-
-
-
Sutton, United Kingdom
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
-
Texas
-
Dallas, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects have had their PIK3CA gene mutation status assessed prior to enrolling into the study
- Subjects must have documented disease progression prior to enrolling into the study
- locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy.
- Age greater than or equal to (>=) 18 years, including males and females;
- Eastern cooperative oncology group (ECOG) performance status (PS) 0-1;
- Adequate organ function;
- Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration;
- Ability to swallow oral medications;
- Ability to understand and willingness to sign informed consent prior to initiation of any study procedures;
- For women of child-bearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration
Exclusion Criteria:
- Diagnosis of primary brain tumor; untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;
- Received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug;
- Have received a systemic corticosteroid within one week prior to the first administration of study drug;
- Clinically significant cardiac disease;
- Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug;
- Malabsorption ;
- Poorly controlled diabetes mellitus;
- Pregnancy (positive serum or urine pregnancy test) or breast feeding;
- Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;
- Failed to recover from the reversible effects of prior anticancer therapies;
- Have received a selective phosphoinositide-3-kinase alpha isoform (PI3K-alpha) inhibitor
- Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system (CNS) disease, active infection, or any other condition that could compromise the subject's participation in the study
- Known human immunodeficiency virus (HIV) infection
- Have a secondary malignancy within the last 3 years prior to first dose of study drug, excluding treated non-melanoma skin cancer, carcinoma in situ, or locally-treated prostate cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
TAK-117 administered once a day orally
|
oral administration of TAK-117, daily and intermittent schedules.
|
Experimental: Arm B
TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
|
oral administration of TAK-117, daily and intermittent schedules.
|
Experimental: Arm C
TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
|
oral administration of TAK-117, daily and intermittent schedules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of TAK-117
Time Frame: Baseline up to Cycle 1 Day 21
|
MTD is highest dose level of TAK-117 at which no more than 1 out of 6 participants had a dose limiting toxicity (DLT) during first cycle.
DLT was any 1 of following events occurring within first 21 days of Cycle 1 of TAK-117 administration, Grade 2: fasting hyperglycemia for >14 days.
Grade 3: nausea and/or vomiting/diarrhea for >7 days; rash for >7 days; thrombocytopenia with bleeding; fasting hyperglycemia for >24 hours(hr).
Grade >=3:nonhematologic toxicity considered clinically significant by investigator.
Grade 4:neutropenia (absolute neutrophil count <=0.5*10^9per liter[/L]) for >7 days in absence of growth factor support; neutropenia of any duration accompanied with fever >=38.5 degree Celsius and/or systemic infection.
Grade >=4:hematologic toxicity.
Inability to administer at least 75% of planned doses of TAK-117 within Cycle 1 due to its related toxicity;Any clinically significant occurrence that investigators and sponsor agreed would place participants at undue safety risk.
|
Baseline up to Cycle 1 Day 21
|
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1
Time Frame: Baseline up to Cycle 27 Day 45
|
Baseline up to Cycle 27 Day 45
|
|
Number of Participants With Highest Level of TEAEs Severity
Time Frame: Baseline up to Cycle 27 Day 45
|
Severity of AEs was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 as follow: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (life-threatening); Grade 5 (fatal).
|
Baseline up to Cycle 27 Day 45
|
Number of Participants With Clinically Meaningful Changes in Laboratory Values
Time Frame: Baseline up to Cycle 27 Day 45
|
Baseline up to Cycle 27 Day 45
|
|
Number of Participants With Clinically Meaningful Changes in Vital Signs
Time Frame: Baseline up to Cycle 27 day 45
|
Baseline up to Cycle 27 day 45
|
|
Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)
Time Frame: Baseline up to Cycle 27 Day 45
|
Baseline up to Cycle 27 Day 45
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
The estimate of the ORR is calculated as crude percentage of participants who's best overall response is complete response (CR) or partial response (PR).
Objective response (CR and PR) as determined by the participants best tumor response was assessed using response evaluation criteria in solid tumors (RECIST) version 1.1.
As per RECIST version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease.
All nodes, both target and non-target, must decrease to normal (short axis <10 millimeter [mm]).
No new lesions.
PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions.
The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.
No unequivocal progression of non-target disease.
No new lesions.
Stable disease was defined as not qualifying for CR, PR, and progressive disease (PD).
|
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
Duration of Objective Response
Time Frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
Duration of response was to be calculated for participants who achieved CR or PR.
Duration of objective response was defined as the number of days from the start date of PR or CR (whichever response was achieved first) to the first date that PD or disease progression was objectively documented.
The duration of objective response was to be right-censored for participants who achieved CR or PR and met 1 of the following conditions: Non-protocol anticancer treatment started before documentation of PD; Documented PD after more than 1 missed disease assessment visit; Alive and did not have documentation of PD before a data analysis cutoff date.
|
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
Clinical Benefit Rate (CBR)
Time Frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
Clinical benefit rate was defined as the participants who achieved stable disease (SD) for at least 15 weeks, CR, or PR.
The estimate of the CBR was calculated as crude percentage of participants whose best ORR was CR, PR or SD for at least 90 days.
|
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
|
Cmax: Maximum Observed Plasma Concentration for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
T 1/2z: Terminal Disposition Phase Half-life for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
%AUC Extrapolated: Percentage of Area Under Concentration-extrapolated
Time Frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
|
|
Percent Change From Baseline in Pharmacodynamic Markers
Time Frame: Cycle 1 Day 8
|
Pharmacodynamic markers included phosphorylated ribosomal protein S6 (PS6), phosphorylated eukaryotic initiation factor 4E-binding protein 1 (P4EBP1), phosphorylated N-myc downstream regulated gene 1 (PNDRG1), phosphorylated proline-rich AKT substrate of 40 kilodaltons (PPRAS40), and phosphorylated serine/threonine protein kinase AKT (PAKT).
Analysis population (n) for each skin biopsy biomarker is as follow: P4EBP1 (n=6,6,6,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PAKT and PNDRG1 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 6,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PS6 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)."n" for each tumor tissue biomarkers is as follow: P4EBP1, PAKT, PNDRG1, and PS6 (n=1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0).
|
Cycle 1 Day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
August 11, 2011
First Submitted That Met QC Criteria
October 7, 2011
First Posted (Estimate)
October 10, 2011
Study Record Updates
Last Update Posted (Actual)
March 9, 2017
Last Update Submitted That Met QC Criteria
January 13, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INK1117-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced Solid Tumors | Metastatic Solid TumorsChina
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
OBI Pharma, IncTerminatedLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States, Taiwan
-
University of AlbertaWithdrawnLocally Advanced Solid Tumors | Metastatic Solid TumorsCanada
Clinical Trials on TAK-117
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Nonhematologic MalignanciesUnited States, Spain, United Kingdom
-
argenxCompleted
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Millennium Pharmaceuticals, Inc.CompletedClear-cell Metastatic Renal Cell CarcinomaSpain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
-
Joyce O'ShaughnessyTakedaCompletedTriple Negative Breast CancerUnited States
-
Yonsei UniversityCompleted
-
Minerva NeurosciencesCompletedMajor Depressive DisorderUnited States, Bulgaria, Finland, Georgia, Moldova, Republic of, Poland, Ukraine
-
Guangzhou University of Traditional Chinese MedicineUnknown
-
Guangzhou University of Traditional Chinese MedicineLiaoning Tumor Hospital & Institute; Zhongshan People's Hospital, Guangdong... and other collaboratorsUnknownOcclusion and Stenosis of Unspecified Cerebral Artery
-
Millennium Pharmaceuticals, Inc.TerminatedAdvanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaUnited States, Spain